Kiel Laboratories®, Inc., a United States pharmaceutical research, development and manufacturing company, is to invest over £5 million to set up a manufacturing facility in Carrickfergus. Kiel Laboratories is beginning recruitment for its new plant and is expected to create 100 jobs within two to three years.
The inward investment is being backed by Invest Northern Ireland and was announced today by Ian Pearson, MP, Northern Ireland Office Minister with responsibility for Enterprise, Trade and Investment.
The focus of the new manufacturing facility will be utilization of the patent-pending “Tannate Conversion Technology” (TCT™) to manufacture extended-release prescription products for the treatment of coughs, colds and allergies. Kiel Laboratories develops and maintains a variety of liquid and solid-dosage pharmaceutical products.
Welcoming the investment, the Minister said: “This investment is a boost to Carrickfergus and to Northern Ireland as a whole. It will strengthen our healthcare and biotechnology sector, a priority sector for Invest NI, and one that has huge potential for wealth creation.
“Kiel Laboratories is a young, dynamic, fast growing company that has benefited from its focus on research and development. The transfer of this unique technology to Carrickfergus and the potential for future collaboration between Kiel Laboratories and our local universities makes this an exciting project for Northern Ireland.
“Invest Northern Ireland is working strenuously to attract high-quality inward investment to Northern Ireland, and despite the depressed global economy has maintained its share of British Isles inward investment.
“An important element in persuading Kiel Laboratories to come to Northern Ireland is the customised package available to them to locate in here and the ongoing support to help them grow,” the Minister added.
Initially, the total output from the Northern Ireland plant will be sold in the USA, and the high calibre facility in Northern Ireland will position the company for future market entry into Europe as part of its long-term strategy.
Dr. Jeffrey S. Kiel, Founder and President of Kiel Laboratories, Inc., commented: “We’ve been considering establishing a European presence for a number of years, and the success of our TCT products has added to our need for additional manufacturing capacity. This investment diversifies our manufacturing ability, adds capacity and provides a gateway to Europe for our future development.
“After exploring a number of locations, we chose Northern Ireland because of the ability to attract and retain high calibre employees, the potential for collaboration with the local universities, the very favorable pharmaceutical regulatory environment in the UK, and the support available from Invest NI.
“We are anticipating substantial growth over the next few years and will be investing further in capital expansion. We believe that the quality of the people in Northern Ireland and the support offered to businesses will give us the very best chance of achieving our ambitious targets.”